

Practitioner's Docket No.: 868\_012

**10/587320**  
**IAP5 Rec'd PCT/PTO 26 JUL 2006**

**IN THE UNITED STATES ELECTED OFFICE (EO/US)**

International Application No.: PCT/JP2005/001187

International Filing Date: 28 January 2005 (28.01.2005)


Earliest Priority Date Claimed: 30 January 2004 (30.01.2004)

Title of Invention: PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETIC  
MACULOPATHY

Applicant(s) for DO/US: KATO, Noriaki; NAGANO, Hiroshi; TANIKO, Kaori and  
JOMORI, Takahito

Mail Stop PCT  
Attention: EO/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 addressed to the Mail Stop PCT, Attention: EO/US, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 26, 2006 under "EXPRESS MAIL" mailing label number EV 682620 367 US.

  
Elizabeth A. VanAntwerp

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449.

Enclosed is a copy of an International Search Report bearing a mailing date of July 12, 2005 from a corresponding international patent application, and the U.S. PTO is directed thereto for a concise statement of possible relevance of the references cited therein.

In compliance with the concise explanation requirement under 37 CFR § 1.98(a)(3) for foreign language documents, Applicants submit the following:

1. Japanese Laid-Open Patent Publication No. 03-072226 C2 (Ref. AE) corresponds to U.S. Patent No. 4,740,517 (Ref. AB); and

10/587320

2. Japanese Laid-Open Patent Publication No. 08-231549 A1 (Ref. AF) corresponds to European Patent Application Publication No. 0 719 556 A2 (Ref. AG).


LAP 5 Rec'd PCT/PTO 26 JUL 2006

The above information is presented so that the Patent and Trademark Office may, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that these references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

July 26, 2006

Date

Respectfully submitted,



Stephen P. Burr  
Reg. No. 32,970

SPB/eav

BURR & BROWN  
P.O. Box 7068  
Syracuse, NY 13261-7068

Customer No.: 025191  
Telephone: (315) 233-8300  
Facsimile: (315) 233-8320

IAF5 Rec'd PCT/PTO 26 JUL 2006

Form PTO-1449  US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				<b>10/587320</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	1	Attorney Docket No.	
				868_012	

**U.S. PATENT DOCUMENTS**

Exam. Initial		Document Number	Date	Name	Our Docket No.	Class	Sub Class	Filing Date
	AA	6,479,729	11-12-2002	Campochiaro et al.				
	AB	4,740,517	04-26-1988	Kurono et al.				

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Sub Class	Translation	Abstract
	AC	07-242547 A1	09-19-1995	JP				
	AD	61-200991 A1	09-10-1986	JP				
	AE	03-072226 C2	11-18-1991	JP				
	AF	08-231549 A1	09-10-1996	JP				
	AG	0 719 556 A2	07-03-1996	EP				

**OTHER DOCUMENTS**

*(Including Author, Title, Date, Pertinent Pages etc.)*

	AH	Speicher, Matthew A. et al., "Pharmacologic Therapy for Diabetic Retinopathy," Expert Opinion on Emerging Drugs, Vol. 8, No. 1 (2003), pages 239-250
	AI	Masahiko Akita et al., "Effects of and Aldose Reductase Inhibitor, SNK-860, on the Histopathological Changes of Retinal Tissues in a Streptozotocin-Induced Rat Model," Acta Med. Okayama, Vol. 47, No. 5 (1993), pages 299-304
	AJ	Irina G. Obrosova et al., "Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats," Diabetes, Vol. 52, No. 3 (2003), pages 864 to 871
	AK	Giebel, S.J. et al., "Upregulation of Extracellular Proteinases and Angiopoietin 2 during Blood-Retinal-Barrier Alteration in the Diabetic Rat Model," ARVO Annual Meeting Abstract Search and Program Planner, Vol. 2003, pp. Abstract No. 3903
	AL	Sima, J. et al., "Angiostatin Decrease Vascular Leakage by Down-Regulating VEGF Expression," ARVO Annual Meeting Abstract Search and Program Planner, Vol. 2003, pp. Abstract No. 363.

Examiner:		Date Considered:	
-----------	--	------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.